Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Allarity Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Allarity Therapeutics, Inc.

ALLR

Allarity Therapeutics, Inc.

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company developing novel anti-cancer therapeutics and companion diagnostics. Its proprietary Drug Response Predictor (DRP®) platform identifies gene expression signatures to predict patient response to cancer drugs, enabling targeted treatment and streamlined clinical trials. The company’s lead asset, stenoparib, is a dual PARP and tankyrase inhibitor in development for advanced ovarian cancer, supported by DRP®-guided patient selection.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Allarity Therapeutics, Inc.

1
1
Allarity Therapeutics, Inc. Allarity Therapeutics Reports Q1 2026 Financial Results with Increased Revenue and Net Loss

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Allarity Therapeutics, Inc. Allarity Therapeutics Reports $11.2 Million Net Loss, First Revenue from Drug Response Predictor

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Allarity Therapeutics, Inc. Allarity Therapeutics Reports Improved Financial Results for Q3 2025 with Reduced Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Allarity Therapeutics, Inc. Allarity Therapeutics Reports Q2 2025 Financial Results with Increased Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Allarity Therapeutics, Inc. Allarity Therapeutics Reports $2.7 Million Net Loss in Q1 2025, Cash Position Increases to $27.7 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Allarity Therapeutics, Inc. Allarity Therapeutics Reports $24.5 Million Net Loss and Strategic Focus on Stenoparib

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Allarity Therapeutics, Inc. Allarity Therapeutics Reports Improved Cash Position, Increased Operating Expenses, and Regulatory Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments